The Briefing Headlines Oct 19

Ozempic: The good, the bad, the ugly

Monday Headlines: 
Jordon Steele-John releases lengthy statement, says he’s not on leave
Violent cost of living protests sweep France with more than 2000 arrested
Trump endorses Netanyahu as his administration calls for more to be done over Israeli settler violence in the West Bank
Pope Leo makes first public appearance since lung surgery
Katie Zachariah fired after five days in White House press secretary role

Deep Dive: They started out treating type 2 diabetes. Now hundreds of thousands of Australians are taking them, many for a completely different reason.  

GLP-1s. You probably know them as Ozempic, Wegovy and Mounjaro.  

And the more people sign up, the longer the fine print gets. There are side effects GPs are still learning about, prices many can’t afford, and growing concern about online clinics posting pens to people they’ve never met.  

So, years after they went from diabetes medication to weight-loss wonder drug... what do we actually know about them?  

In this episode of The Briefing, Chris Spyrou is joined by Dr Michael Wright, President of the Royal Australian College of GPs, to unpack what we’ve learnt about these drugs, who should be taking them, and who definitely shouldn’t. 

Follow The Briefing:  
TikTok: @thebriefingpod  
Instagram: @thebriefingpodcast  
YouTube: @TheBriefingPodcast  

Monday Headlines:&nbsp;
<ul>
<li>Jordon Steele-John releases lengthy statement, says he&rsquo;s not on leave</li>
<li>Violent cost of living protests sweep France with&nbsp;more than&nbsp;2000 arrested</li>
<li>Trump endorses Netanyahu as his administration calls for more to be done over Israeli settler violence in the West Bank</li>
<li>Pope Leo makes first public appearance since lung surgery</li>
<li>Katie Zachariah fired after five days in White House press secretary role</li>
</ul>
Deep Dive: They started out treating type 2 diabetes. Now hundreds of thousands of Australians are taking them, many for a completely different reason.&nbsp;&nbsp;
GLP-1s. You probably know them as Ozempic, Wegovy and Mounjaro.&nbsp;&nbsp;
And the more people sign up, the longer the fine print gets. There are side effects GPs are still learning about, prices many can&rsquo;t afford, and growing concern about online clinics posting pens to people they&rsquo;ve never met.&nbsp;&nbsp;
So, years after they went from diabetes medication to weight-loss wonder drug... what do we actually know about them?&nbsp;&nbsp;
In this episode of The Briefing, Chris Spyrou is joined by Dr Michael Wright, President of the Royal Australian College of GPs, to unpack what we&rsquo;ve learnt about these drugs, who should be taking them, and who definitely shouldn&rsquo;t.&nbsp;
Follow The Briefing: &nbsp; TikTok:&nbsp;<a href="https://www.tiktok.com/@thebriefingpod">@thebriefingpod</a> &nbsp; Instagram:&nbsp;<a href="https://www.instagram.com/thebriefingpodcast/">@thebriefingpodcast</a> &nbsp; YouTube:&nbsp;<a href="https://www.youtube.com/@TheBriefingPodcast">@TheBriefingPodcast</a> &nbsp;

We’re your friends in news. 

Sacha Barbour Gatt and Chris Spyrou wake up early to bring you all the important daily news headlines. 

Then, we deep dive on an essential news story that'll make you feel smarter about the world. 

Listen every weekday to know more in minutes.

We&rsquo;re your friends in news.&nbsp;
Sacha Barbour Gatt and Chris Spyrou wake up early to bring you all the important daily news headlines.&nbsp;
Then, we deep dive on an essential news story that'll make you feel smarter about the world.&nbsp;
Listen every weekday to know more in minutes.